Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007.

In this report, the Commission provides biokinetic and dosimetric models for 33 radiopharmaceuticals, as well as recommendations related to breast feeding for mothers who have undergone a nuclear medicine investigation. The report is based on Addenda 3-9 to Publication 53. Addenda 3-7 have been available on the ICRP website (www.icrp.org) as interim reports. The work has been carried out by a Joint Task Group of ICRP Committees 2 and 3. This publication provides biokinetic models, absorbed doses, and effective doses for the following radiopharmaceuticals: 11C-acetate; 11C-amino acids; 11C-brain receptor substances; 11C-methionine; 18F-amino acids; 18F-FET; 18F-FDG; 111In-monoclonal antibodies/fragments; 123I-fatty acids (BMIPP, IPPA); 123I-monoclonal antibodies/fragments; 131I-monoclonal antibodies/fragments; and 201Tl-ion. The publication also provides realistic maximum models for 11C- and 18F-substances, for which no specific models are available.

[1]  P. Franken,et al.  Intra-individual comparison of 3(R)-BMIPP and 3(S)-BMIPP isomers in humans. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  H. Kung,et al.  Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  H. Herzog,et al.  Whole-body kinetics and dosimetry ofl-3-[123I]iodo-α-methyltyrosine , 1997, European Journal of Nuclear Medicine.

[4]  M. Marmion,et al.  Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q12. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  R. Walsh,et al.  Comparison of technetium 99m Q12 and thallium 201 for detection of angiographically documented coronary artery disease in humans , 1994, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[6]  Alistair Mackenzie Reduction of extremity dose in the radiopharmacy. , 1997, Nuclear medicine communications.

[7]  D. Comar,et al.  Labelling and metabolism of methionine-methyl-11C , 2004, European Journal of Nuclear Medicine.

[8]  Xiaowei Zhu Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin). , 2004, Seminars in nuclear medicine.

[9]  Alan A. Wilson,et al.  Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.

[10]  Jonathan M. Links,et al.  Comparison of [11C]Diprenorphine and [11C]Carfentanil Binding to Opiate Receptors in Humans by Positron Emission Tomography , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  H. Atkins,et al.  Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties. , 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  R. Walovitch,et al.  Intrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  K. Hofer Biophysical aspects of Auger processes--A review. , 1996, Acta oncologica.

[15]  S. Mattsson,et al.  Excretion of radionuclides in human breast milk after the administration of radiopharmaceuticals. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Michael G. Stabin,et al.  Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters , 1997, European Journal of Nuclear Medicine.

[17]  C. Martin,et al.  Application of ALARP to extremity doses for hospital workers. , 2003, Journal of radiological protection : official journal of the Society for Radiological Protection.

[18]  W. Oyen,et al.  Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci , 1995, European Journal of Nuclear Medicine.

[19]  Biodistribution and radiation dosimetry of the dopamine transporter ligand. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Leggett,et al.  Suggested reference values for regional blood volumes in humans. , 1991, Health physics.

[21]  M E Phelps,et al.  Compartment model for measuring myocardial oxygen consumption using [1-11C]acetate. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  H. M. Deloar,et al.  Estimation of internal absorbed dose of l-[methyl-11C]methionine using whole-body positron emission tomography , 1998, European Journal of Nuclear Medicine.

[23]  Michael Ljungberg,et al.  Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[25]  I. Mena,et al.  Biodistribution, dosimetry, and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  F. Smith,et al.  Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Jeroen J. Bax,et al.  Evaluation of heart-to-organ ratios of 123I-BMIPP and the dimethyl-substituted 123I-DMIPP fatty acid analogue in humans. , 1997, Nuclear medicine communications.

[28]  K Wienhard,et al.  F-Dopa as an amino acid tracer to detect brain tumors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  R. Leggett,et al.  A proposed blood circulation model for Reference Man. , 1995, Health physics.

[30]  K. Dutschka,et al.  Biochemical concept and synthesis of a radioiodinated phenylfatty acid for in vivo metabolic studies of the myocardium , 1980, European Journal of Nuclear Medicine.

[31]  M. Prescott,et al.  Uptake, localization, and dosimetry of 111in and 201tl in human testes. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  J. Baron,et al.  Regional Specific Binding of [11C]RO 15 1788 to Central Type Benzodiazepine Receptors in Human Brain: Quantitative Evaluation by PET , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  S. Reske,et al.  Assessment of Regional Myocardial Uptake and Metabolism of ω-(p-123I-Phenyl) Pentadecanoic Acid with Serial Single-Photon Emission Tomography , 1982, Nuklearmedizin.

[34]  M. Stabin,et al.  Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  L. Feinendegen,et al.  Dosimetry and risk from low‐ versus high‐LET radiation of Auger events and the role of nuclide carriers , 2004, International journal of radiation biology.

[36]  Tim Shackleton,et al.  Radionuclide and Radiation Protection Data Handbook , 1999 .

[37]  H. Kung,et al.  Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  H R Schelbert,et al.  Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. , 1990, Circulation.

[39]  Terry Smith,et al.  Dosimetry of intravenously administered oxygen-15 labelled water in man: a model based on experimental human data from 21 subjects , 1994, European Journal of Nuclear Medicine.

[40]  M. Andreeff,et al.  RADIATION PROTECTION IN RADIOSYNOVECTOMY OF THE KNEE , 2005, Health physics.

[41]  A. Bischof Delaloye,et al.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? , 1995, European Journal of Nuclear Medicine.

[42]  P. Cumming,et al.  Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. , 1986, Life sciences.

[43]  Wolfgang Wadsak,et al.  Biological evaluation of 2'-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. , 2004, Nuclear medicine and biology.

[44]  G. Firnau,et al.  Estimation of the radiation dose in man due to 6-[18F]fluoro-L-dopa. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  F. Vanhavere,et al.  Personal dose monitoring in hospitals: global assessment, critical applications and future needs. , 2007, Radiation protection dosimetry.

[46]  D. Hastings,et al.  An assessment of finger doses received by staff while preparing and injecting radiopharmaceuticals. , 1997, Nuclear medicine communications.

[47]  S. Alyafei,et al.  Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  B. Bhatt,et al.  EXTREMITY DOSIMETRY FOR RADIATION WORKERS HANDLING UNSEALED RADIONUCLIDES IN NUCLEAR MEDICINE DEPARTMENTS IN INDIA , 2007, Health physics.

[49]  M. Goodman,et al.  New radioiodinated methyl-branched fatty acids for cardiac studies , 2004, European Journal of Nuclear Medicine.

[50]  K. Bergström,et al.  Biodistribution and radiation dosimetry of [123I]ADAM in healthy human subjects: preliminary results , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  H. Herzog,et al.  Pharmacokinetics of thallium-201 in normal individuals after routine myocardial scintigraphy. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  P. Plato,et al.  Influence of Dosemeter Positioning on Reported Doses to the Upper Extremities , 1985 .

[54]  C. Halldin,et al.  Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  G. Denardo,et al.  Quo vadis radioimmune imaging? , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  H. Herzog,et al.  Absolute quantification of pharmacokinetic distribution of RES colloids in individuals with normal liver function , 1987, Nuclear medicine communications.

[57]  S. Mattsson,et al.  Biokinetics and radiation dosimetry for patients undergoing a glycerol tri[1-14C]oleate fat malabsorption breath test. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[58]  J. Štěpánek,et al.  Auger-electron spectra of radionuclides for therapy and diagnostics. , 1996, Acta oncologica.

[59]  Lawrence N. Rothenberg,et al.  National Council on Radiation Protection and Measurements (NCRP) Scientific Committee 72-Radiation Protection in Clinical Mammography: A Progress Report , 1983, Other Conferences.

[60]  M Berman,et al.  A schema for absorbed-dose calculations for biologically-distributed radionuclides. , 1968, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  E P Krenning,et al.  Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  J. Robertson Methods of Assessment of Absorbed Dose in Clinical Use of Radionuclides, ICRU Report 32 , 1980 .

[63]  Bernhard Sattler,et al.  Age-specific cerebral perfusion in 4- to 15-year-old children: a high-resolution brain SPET study using 99mTc-ECD , 1997, European Journal of Nuclear Medicine.

[64]  B. Långström,et al.  (3-N-[11C]methyl)spiperone, a ligand binding to dopamine receptors: radiochemical synthesis and biodistribution studies in mice. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  E. Länsimies,et al.  The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane , 2004, European Journal of Nuclear Medicine.

[66]  G. D. Gallamore NUCLEAR MEDICINE-FACTORS INFLUENCING THE CHOICE AND USE OF RADIONUCLIDES IN DIAGNOSIS AND THERAPY , 1983 .

[67]  K. Britton,et al.  Radioimmunoscintigraphy in tumour identification. , 1987, Cancer surveys.

[68]  Ws Snyder,et al.  MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs , 1975 .

[69]  G. T. Krishnamurthy,et al.  Radiation-dose calculation for five Tc-99m IDA hepatobiliary agents. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[70]  K F Eckerman,et al.  Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. , 1994, Health physics.

[71]  B. Shleien,et al.  Handbook of health physics and radiological health , 1998 .

[72]  M. Peterson Radioiodine treatment of hyperthyroidism. , 2006, Clinical techniques in small animal practice.

[73]  R. Dannals,et al.  Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  M. Hays,et al.  A mathematical model for the distribution of fluorodeoxyglucose in humans. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  D. W. Anderson,et al.  Use of thermoluminescent dosimeters for measurement of dose to the hands of nuclear medicine technicians. , 1972, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[76]  M. Kraut,et al.  Kinetic Analysis of [11C]McN5652: A Serotonin Transporter Radioligand , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[77]  T. Ishikawa,et al.  Bladder wall radiation dose in humans from fluorine-18-FDOPA. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  A. Mackie,et al.  Breast milk activity during early lactation following maternal 99Tcm macroaggregated albumin lung perfusion scan. , 2002, British Journal of Radiology.

[79]  M. Prescott,et al.  Excretion of iodine-123-hippuran, technetium-99m-red blood cells, and technetium-99m-macroaggregated albumin into breast milk. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  P. Shreve,et al.  Imaging of the pancreas and related diseases with PET carbon-11-acetate. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[81]  M. Ferrari,et al.  Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[82]  Colin J. Martin,et al.  A multi-centre study of dispensing methods and hand doses in UK hospital radiopharmacies , 2005, Nuclear medicine communications.

[83]  A. Luxen,et al.  PET radiopharmaceuticals in Europe: Current use and data relevant for the formulation of summaries of product characteristics (SPCs) , 1995, European Journal of Nuclear Medicine.

[84]  S. Mattsson,et al.  Accuracy of the quantification of organ activity from planar gamma camera images. , 2003, Cancer biotherapy & radiopharmaceuticals.

[85]  J. Hatazawa,et al.  Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  M Schwaiger,et al.  Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[87]  Michael G Stabin,et al.  PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT , 2003, Health physics.

[88]  W E Bolch,et al.  S values for radionuclides localized within the skeleton. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  F. Knapp,et al.  Iodine-123-labelled fatty acids for myocardial single-photon emission tomography: current status and future perspectives , 1995, European Journal of Nuclear Medicine.

[90]  Alan A. Wilson,et al.  Derivatives of WAY 100635 as potential imaging agents for 5-HT1A receptors: syntheses, radiosyntheses, and in vitro and in vivo evaluation. , 1998, Nuclear medicine and biology.

[91]  P. Brust,et al.  Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET. , 1995, Nuclear medicine and biology.

[92]  Stephen R. Thomas,et al.  Radiation-absorbed dose from 201Tl-thallous chloride. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  P. Franken,et al.  Cardiac SPECT with iodine-123-labeled fatty acids: evaluation of myocardial viability with BMIPP. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[94]  Z. Rattner,et al.  Tc-99m HIDA dosimetry in patients with various hepatic disorders. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[95]  J. L. Coffey,et al.  Calculating dose from remaining body activity: a comparison of two methods. , 1979, Medical physics.

[96]  H. D. Roedler,et al.  Internal radiation dose in diagnostic nuclear medicine , 1981 .

[97]  C. Rowe,et al.  Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[98]  H. Sakahara,et al.  Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice. , 1989, Cancer research.

[99]  P. Mountford,et al.  A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. , 1989, Nuclear medicine communications.

[100]  A. D. Roberts,et al.  Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[101]  L. Edenbrandt,et al.  Distribution and Dosimetry of 111In Dtpa-D-Phe-Octreotide in Man Assessed by Whole Body Scintigraphy , 1994, Acta radiologica.

[102]  G. Sedvall,et al.  Cerebral uptake of 11C—Ro 15—1788 and its acid metabolite 11C—Ro 15—3890; PET study in healthy volunteers , 1989 .

[103]  D. Taylor,et al.  Investigations of 18F-p-fluorophenylalanine for pancreas scanning. , 1973, The British journal of radiology.

[104]  A. Elliott,et al.  A study of doses to the hands during dispensing of radiopharmaceuticals , 2000, Nuclear medicine communications.

[105]  M. Cooper,et al.  Technetium-99m-labeled n-(2,6-dimethylphenylcarbamoylmethyl) iminodiacetic acid (tc-99m HIDA): a new radiopharmaceutical for hepatobiliary imaging studies. , 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[106]  S. Houle,et al.  Imaging the 5-HT(1A) receptors with PET: WAY-100635 and analogues. , 2000, Nuclear medicine and biology.

[107]  C. Martin,et al.  Reductions in finger doses for radiopharmaceutical dispensing afforded by a syringe shield and an automatic dose dispenser. , 1999, Nuclear medicine communications.

[108]  H. D. Roedler,et al.  Dose to target organs from remaining body activity: Results of the formally exact and approximate solution , 1977 .

[109]  L. K. Harding,et al.  Staff radiation doses associated with nuclear medicine procedures - a review of some recent measurements , 1990, Nuclear medicine communications.

[110]  S. Reske 123I-phenylpentadecanoic acid as a tracer of cardiac free fatty acid metabolism. Experimental and clinical results. , 1985, European heart journal.

[111]  P. Grasby,et al.  Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. , 1996, Nuclear medicine and biology.

[112]  W. S. Snyder,et al.  Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. , 1974, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[113]  D. McClain,et al.  Intravenous fentanyl kinetics , 1980, Clinical pharmacology and therapeutics.

[114]  M. V. Niekerk,et al.  The excretion of radiopharmaceuticals in human breast milk: additional data and dosimetry , 1994, European Journal of Nuclear Medicine.

[115]  Masatoshi Itoh,et al.  Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d- glucose using whole-body positron emission tomography and magnetic resonance imaging , 1998, European Journal of Nuclear Medicine.

[116]  Hans-Georg Buchholz,et al.  [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors , 2001, European Journal of Nuclear Medicine.

[117]  E. Zuckerman,et al.  Quantitation of liver and spleen uptake of (99m)Tc-phytate colloid using SPECT: detection of liver cirrhosis. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[118]  B. Shepstone,et al.  Kinetics and dosimetry of thallium-201 in human testes. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[119]  K. Endo,et al.  Radiation dosimetry for indium-111-pentetreotide. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[120]  H. Griffiths General Concepts for the Dosimetry of Internally Deposited Radionuclides. Report no. 84 , 1986 .

[121]  A. Luxen,et al.  Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa. , 1994, European journal of pharmacology.

[122]  C. Martin,et al.  Investigation using an advanced extremity gamma instrumentation system of options for shielding the hand during the preparation and injection of radiopharmaceuticals. , 2003, Journal of radiological protection : official journal of the Society for Radiological Protection.

[123]  W. Oldendorf,et al.  N-isopropyl-[123I] p-iodoamphetamine: single-pass brain uptake and washout; binding to brain synaptosomes; and localization in dog and monkey brain. , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[124]  J. Ulanski,et al.  Radioactivity in breast milk following 111In-octreotide , 2000, Nuclear medicine communications.

[125]  H D Humes,et al.  Carbon-11-acetate PET imaging in renal disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[126]  Icrp Chapters 1–5 , 2006 .

[127]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[128]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[129]  D. Le Guludec,et al.  Cell Irradiation caused by diagnostic nuclear medicine procedures: dose heterogeneity and biological consequences , 1999, European Journal of Nuclear Medicine.

[130]  M. Wrzesień,et al.  Hand exposure to ionising radiation of nuclear medicine workers. , 2008, Radiation protection dosimetry.

[131]  Christer Halldin,et al.  A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.

[132]  W E Bolch,et al.  A revised dosimetric model of the adult head and brain. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[133]  L. Jacobsson,et al.  Radioiodine treatment of hyperthyroidism in a pregnant women. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[134]  B. Beuthien-Baumann,et al.  [Investigations of radiation exposure of the medical personnel during F-18-FDG PET studies]. , 2000, Nuklearmedizin. Nuclear medicine.

[135]  O. Mundler,et al.  Technologist radiation exposure in routine clinical practice with 18F-FDG PET. , 2005, Journal of nuclear medicine technology.

[136]  Y. Yonekura,et al.  [A Phase 1 study of beta-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP)]. , 1991, Kaku igaku. The Japanese journal of nuclear medicine.

[137]  C. Neil The question of radiation exposure to the hand from handling 99mTc. , 1969, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[138]  J C Mazziotta,et al.  The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[139]  G. Mannaerts,et al.  Alpha-oxidation of 3-methyl-substituted fatty acids and its thiamine dependence. , 2003, European journal of biochemistry.

[140]  M. Bronskill Radiation dose estimates for interstitial radiocolloid lymphoscintigraphy. , 1983, Seminars in nuclear medicine.

[141]  B. Cronin,et al.  The Technologist’s Perspective , 2005 .

[142]  Eva Forssell-Aronsson,et al.  Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[143]  D. Comar,et al.  Radiation dosimetry for bolus administration of oxygen-15-water. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[144]  R. Marchesini,et al.  Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose , 1997, European Journal of Nuclear Medicine.

[145]  M. Goodman,et al.  Structurally modified fatty acids: Clinical potential as tracers of metabolism , 2004, European Journal of Nuclear Medicine.

[146]  F Trompier,et al.  Feasibility study of an active extremity dosimetry prototype. , 2005, Radiation protection dosimetry.

[147]  H. Coenen,et al.  Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[148]  A. Bossuyt,et al.  Effect of oral glucose loading on the biodistribution of BMIPP in normal volunteers. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[149]  M G Stabin,et al.  Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[150]  W. Gössner,et al.  Cells at Risk for Dosimetric Modelling Relevant to Bone Tumour Induction , 2000 .

[151]  S. Goddu,et al.  Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[152]  A. Rimpler,et al.  Beta radiation exposure of medical staff and implications for extremity dose monitoring. , 2006, Radiation protection dosimetry.

[153]  S. Mattsson,et al.  EFFECTIVE DOSE FROM RADIOPHARMACEUTICALS. AUTHORS' REPLY , 1993 .

[154]  K. Kluska,et al.  Distribution of equivalent doses to skin of the hands of nuclear medicine personnel. , 2003, Radiation protection dosimetry.

[155]  D. Eshima,et al.  Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations. , 2000, Seminars in nuclear medicine.

[156]  M. Taavitsainen,et al.  Body disappearance and liver mean transit time of 99m-Tc-diethyl-IDA , 1980, European Journal of Nuclear Medicine.

[157]  P. Faulhaber,et al.  Transfer of thallous ion to and from gastrointestinal sections , 1984 .

[158]  A. Luxen,et al.  Production of 6-[18F]fluoro-L-dopa and its metabolism in vivo--a critical review. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[159]  G. Pant,et al.  Finger doses for staff handling radiopharmaceuticals in nuclear medicine. , 2006, Journal of nuclear medicine technology.

[160]  K. F. Eckerman,et al.  Specific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn , 1987 .

[161]  R. Waterhouse,et al.  Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [(18)F]FPS. , 2003, Nuclear medicine and biology.

[162]  A. Kassis The Amazing World of Auger Electrons , 2004, International journal of radiation biology.

[163]  H. D. Roedler,et al.  Accuracy of internal dose calculations with special consideration of radiopharmaceutical biokinetics , 1981 .

[164]  L. K. Harding,et al.  The value of syringe shields in a nuclear medicine department , 1985, Nuclear medicine communications.

[165]  E E Watson,et al.  A model of the peritoneal cavity for use in internal dosimetry. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[166]  H. Kung,et al.  Dosimetry of iodine-123 iodobenzamide in healthy volunteers , 1993, European Journal of Nuclear Medicine.

[167]  I. Gardin,et al.  The Problem of Auger Emitters for Radiological Protection , 2000 .

[168]  K Morita,et al.  The role of fatty acids in cardiac imaging. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[169]  R. Sparks,et al.  Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. , 1997, Health physics.

[170]  A. Luxen,et al.  The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans. , 1990, Life sciences.

[171]  P. Zanzonico,et al.  Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[172]  R. Koeppe,et al.  Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. , 1995, Nuclear medicine and biology.

[173]  A. Penfold,et al.  Radiation dose to the hands in nuclear medicine , 1991, Nuclear medicine communications.

[174]  H. Atkins,et al.  Organic radiopharmaceuticals labeled with isotopes of short half-life. V. 18 F-labeled 5- and 6-fluorotryptophan. , 1972, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[175]  D. Taylor Generic models for radionuclide dosimetry: 11C-, 18F- or 75Se-labelled amino acids. , 2000, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.